October 5, 2015
Avita expands Compassionate Use IDE program for ReCell
FDA allows Avita to expand its Compassionate Use Investigational Device Exemption (IDE) program for ReCell.
Pharmaceuticals, Biotechnology and Life Sciences
Author: Dino Mustafić
October 5, 2015
FDA OKs Alcon’s AcrySof IQ Aspheric IOL with the UltraSert Pre-loaded Delivery System for patients undergoing cataract surgery
Novartis’s Alcon has received US Food and Drug Administration (FDA) approval for its AcrySof IQ Aspheric IOL with the UltraSert Pre-loaded Delivery System for patients undergoing cataract surgery.
October 2, 2015
Antisel SA will distribute Premaitha Healt’s prenatal screening test IONA in Greece and region
Premaitha Health has signed a distribution agreement with Antisel SA, a Greek distributor of scientific products, to provide the IONA test to clinical laboratories in the region.
October 2, 2015
FDA: Accelerated approval for Keytruda for patients with advanced (NSCLC) lung cancer
accelerated approval for Keytruda (pembrolizumab) to treat patients with advanced (metastatic) non-small cell lung cancer (NSCLC)
October 2, 2015
Vectura Group gets €5M upon partner’s work in Europe
Vectura’s partner on the VR876 programme has achieved an important development milestone in Europe, which triggered a cash milestone payment of €5m (circa. £3.6m) to Vectura.
October 2, 2015
Allergan – Humana Research Partnership
Allergan plc, has announced a multi-year research collaboration with Humana Inc. to explore new ideas and ways to improve the health and well-being of patients, members and their caregivers.
October 2, 2015
Pfizer acquisition of GlaxoSmithKline’s vaccines Nimenrix and Mencevax
Pfizer Inc. has announced that it has completed the acquisition of GlaxoSmithKline’s quadrivalent meningococcal ACWY vaccines Nimenrix and Mencevax.
October 2, 2015
Vernalis Acquires U.S. Rights to Moxatag
Vernalis plc has announces that it has acquired the US rights to Moxatag (amoxicillin extended-release tablets) from Pragma Pharmaceuticals, LLC (“Pragma”).
October 2, 2015
Sanofi: Genzyme Opts into Alnylam’s ALN-AT3 Hemophilia Program
Sanofi and its subsidiary Genzyme have announced that Genzyme has elected to opt into Alnylam’s investigational ALN-AT3 hemophilia program for development and potential future commercialization in territories outside of North America and Western Europe.